Please provide your email address to receive an email when new articles are posted on . The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only ...

Advances Amgen (AMGN)'s Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ -- ...

(MENAFN- GetNews) "IgG4-Related Disease Pipeline Insight, 2021" report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of patients ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Uplizna met all primary and secondary endpoints for ...

Sanofi SNY announced that the European Medicines Agency (EMA) has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for treating IgG4-related disease (IgG4-RD). IgG4 ...

Inebilizumab (Uplizna) treatment significantly reduced the risk of flares in patients who had IgG4-related disease (IgG4-RD) with involvement in the pancreas, bile ducts, or liver, according to a post ...

Inebilizumab-cdon, a monoclonal antibody that depletes B cells, reduces the risk for flares without showing any new safety signals in patients with immunoglobulin G4-related disease (IgG4-RD) who have ...

Flare-free, treatment-free complete remission and flare-free, glucocorticoid-free complete remission occurred in more participants in the inebilizumab group than the placebo group. (HealthDay News) — ...

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 Additional orphan designation underscores Sanofi commitment to advancing ...